That's not quite right. Brachysil has already been developed as a treatment (not indicator) for liver cancer. Today's announcement is that they are expanding Brachysil's market to include pancreatic cancer.
Quoting from the announcement: "Pancreatic cancer is one of the most prevalent cancers with over 232,000 new cases on a global basis per annum (Globocan 2002 statistics) and approximately 60% of new cases occurring in the developed world. With an average five year survival of 4%, pancreatic cancer represents a significant unmet clinical need."
Pezz
PSD
psivida limited
